Tags

Type your tag names separated by a space and hit enter

A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
J Am Coll Cardiol. 2014 Aug 12; 64(6):613-21.JACC

Abstract

The prevention of cardiovascular disease (CVD) by using a polypill has gained increasing momentum as a strategy to contain progression of the disease. Since its initial conception just over a decade ago, only a handful of trials have been completed assessing the efficacy and safety of this innovative concept. The results of these trials have supported the viability of the polypill in CVD prevention and management, albeit with a few caveats, essentially related to the lack of evidence on the effect of the polypill to effectively reduce cardiovascular events. The polypill has the potential to control the global health epidemic of CVD by effectively reaching underdeveloped regions of the world, simplifying healthcare delivery, improving cost-effectiveness, increasing medication adherence, and supporting a comprehensive prescription of evidence-based cardioprotective drugs. Major trials underway will provide definitive evidence on the efficacy of the polypill in reducing cardiovascular events in a cost-effective manner. The results of these studies will determine whether a polypill strategy can quell the burgeoning public health challenge of CVD and will potentially provide the evidence to implement an effective, simple, and innovative solution to restrain the global CVD pandemic.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Castellano JM
Cardiovascular Institute, The Mount Sinai Medical Center, New York, New York; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Sanz G
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Fernandez Ortiz A
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Garrido E
Graduate School of Biomedical Sciences at Mount Sinai, New York, New York; Ferrer Internacional, Barcelona, Spain.
Bansilal S
Cardiovascular Institute, The Mount Sinai Medical Center, New York, New York.
Fuster V
Cardiovascular Institute, The Mount Sinai Medical Center, New York, New York; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. Electronic address: valentin.fuster@mountsinai.org.

MeSH

Cardiovascular AgentsCardiovascular DiseasesDrug CombinationsHumansRandomized Controlled Trials as TopicSecondary Prevention

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25104532

Citation

Castellano, José M., et al. "A Polypill Strategy to Improve Global Secondary Cardiovascular Prevention: From Concept to Reality." Journal of the American College of Cardiology, vol. 64, no. 6, 2014, pp. 613-21.
Castellano JM, Sanz G, Fernandez Ortiz A, et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol. 2014;64(6):613-21.
Castellano, J. M., Sanz, G., Fernandez Ortiz, A., Garrido, E., Bansilal, S., & Fuster, V. (2014). A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. Journal of the American College of Cardiology, 64(6), 613-21. https://doi.org/10.1016/j.jacc.2014.06.009
Castellano JM, et al. A Polypill Strategy to Improve Global Secondary Cardiovascular Prevention: From Concept to Reality. J Am Coll Cardiol. 2014 Aug 12;64(6):613-21. PubMed PMID: 25104532.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. AU - Castellano,José M, AU - Sanz,Ginés, AU - Fernandez Ortiz,Antonio, AU - Garrido,Ester, AU - Bansilal,Sameer, AU - Fuster,Valentin, PY - 2014/05/14/received PY - 2014/06/02/revised PY - 2014/06/02/accepted PY - 2014/8/9/entrez PY - 2014/8/12/pubmed PY - 2014/10/7/medline KW - cardiovascular disease KW - fixed-dose combination KW - global cardiovascular health KW - polypill KW - secondary prevention SP - 613 EP - 21 JF - Journal of the American College of Cardiology JO - J Am Coll Cardiol VL - 64 IS - 6 N2 - The prevention of cardiovascular disease (CVD) by using a polypill has gained increasing momentum as a strategy to contain progression of the disease. Since its initial conception just over a decade ago, only a handful of trials have been completed assessing the efficacy and safety of this innovative concept. The results of these trials have supported the viability of the polypill in CVD prevention and management, albeit with a few caveats, essentially related to the lack of evidence on the effect of the polypill to effectively reduce cardiovascular events. The polypill has the potential to control the global health epidemic of CVD by effectively reaching underdeveloped regions of the world, simplifying healthcare delivery, improving cost-effectiveness, increasing medication adherence, and supporting a comprehensive prescription of evidence-based cardioprotective drugs. Major trials underway will provide definitive evidence on the efficacy of the polypill in reducing cardiovascular events in a cost-effective manner. The results of these studies will determine whether a polypill strategy can quell the burgeoning public health challenge of CVD and will potentially provide the evidence to implement an effective, simple, and innovative solution to restrain the global CVD pandemic. SN - 1558-3597 UR - https://www.unboundmedicine.com/medline/citation/25104532/A_polypill_strategy_to_improve_global_secondary_cardiovascular_prevention:_from_concept_to_reality_ DB - PRIME DP - Unbound Medicine ER -